Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13772 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Ki Young Huh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Pharmacogenetics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Seoul National University Bundang Hospital Research Fund.
Abstract (Originalsprache)
Genetic variants affect drug responses, making pre‐emptive genotyping crucial for averting serious adverse events (SAEs) and treatment failure. However, assessing the benefits of pre‐emptive genotyping based on genetic distribution, drug exposure, and demographics is challenging. This study aimed to estimate the population‐level benefits of pre‐emptive genotyping in the Korean population using nationwide cohort data. We reviewed actionable gene‐drug combinations recommended by both the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) as of February 2022, identifying high‐risk phenotypes. We collected reported risk reduction from genotyping and standardized it into population attributable risks. Healthcare reimbursement costs for SAEs and treatment failures were obtained from the Health Insurance Review and Assessment Service Statistics in 2021. The benefits of pre‐emptive genotyping for a specific group were determined by multiplying drug exposure from nationwide cohort data by individual genotyping benefits. We identified 31 gene‐drug‐event pairs, with CYP2D6 and CYP2C19 demonstrating the greatest benefits for both male and female patients. Individuals aged 65–70 years had the highest individual benefit from pre‐emptive genotyping, with $84.40 for men and $100.90 for women. Pre‐emptive genotyping, particularly for CYP2D6 and CYP2C19 , can provide substantial benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, South Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, South Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea.
ORCID-Profile: Ki Young Huh, Sejung Hwang, Joo Young Na, Kyung-Sang Yu, In-Jin Jang, Jae-Yong Chung, Seonghae Yoon
Förderung
- National Research Foundation of Korea
- Seoul National University Bundang Hospital Research Fund
Zitieren
APA
Huh, K. Y., Hwang, S., Na, J. Y., Yu, K. S., Jang, I. J., Chung, J. Y., & Yoon, S. (2024). Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea. Clinical and Translational Science. https://doi.org/10.1111/cts.13772
Vancouver
Huh KY, Hwang S, Na JY, Yu KS, Jang IJ, Chung JY, et al. Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea. Clinical and Translational Science. 2024. doi:10.1111/cts.13772
BibTeX
@article{Huh2024,
author = {Huh, Ki Young and Hwang, Sejung and Na, Joo Young and Yu, Kyung-Sang and Jang, In-Jin and Chung, Jae-Yong and Yoon, Seonghae},
title = {Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13772}
}
EUVIMED